MARKET

GNFT

GNFT

GENFIT S.A.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.79
-0.20
-1.33%
Closed 16:00 03/31 EDT
OPEN
14.60
PREV CLOSE
14.99
HIGH
14.96
LOW
13.97
VOLUME
26.16K
TURNOVER
--
52 WEEK HIGH
26.25
52 WEEK LOW
9.73
MARKET CAP
574.32M
P/E (TTM)
-4.3477
1D
5D
1M
3M
1Y
5Y

GNFT News

More
  • FDA Decisions on 5 Drugs Expected in 2nd Quarter
  • GuruFocus.com · 1d ago
  • Genfit: Near-Term Upside Of 650% As Read-Out Of The Year Approaches
  • Seeking Alpha - Article · 03/24 04:45
  • B. Riley FBR Maintains Buy on Genfit, Lowers Price Target to $34
  • Benzinga · 03/13 11:42
  • Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
  • MotleyFool.com · 03/09 15:30

Industry

Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.25%

Hot Stocks

Symbol
Price
%Change

About GNFT

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
More

Webull offers kinds of Genfit SA (ADR) stock information, including NASDAQ:GNFT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNFT stock news, and many more online research tools to help you make informed decisions.